State Street
SGP

State Street’s SpyGlass Pharma SGP Stock Holding History

State Street’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62M Buy
117,561
+100,311
+582% +$2.18M ﹤0.01% 3249
2026
Q1 		$447K Buy
+17,250
New +$464K ﹤0.01% 3688

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street's SGP Position: Q2 2026 in Review

State Street increased its SpyGlass Pharma (SGP) stake by 582% in Q2 2026, buying an estimated $2.18M and bringing the position to 117,561 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #3249.

State Street first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • State Street held 117,561 shares of SpyGlass Pharma worth $2.62M as of Q2 2026.
  • State Street bought 100,311 SpyGlass Pharma shares in Q2 2026, an estimated $2.18M.
  • SpyGlass Pharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3249 holding.
  • State Street first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.